These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

471 related items for PubMed ID: 28494528

  • 1. A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function.
    Yang H, Woo HY, Lee SK, Han JW, Jang B, Nam HC, Lee HL, Lee SW, Song DS, Song MJ, Oh JS, Chun HJ, Jang JW, Lozada A, Bae SH, Choi JY, Yoon SK.
    Clin Mol Hepatol; 2017 Jun; 23(2):128-137. PubMed ID: 28494528
    [Abstract] [Full Text] [Related]

  • 2. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lee JM, Jang BK, Lee YJ, Choi WY, Choi SM, Chung WJ, Hwang JS, Kang KJ, Kim YH, Chauhan AK, Park SY, Tak WY, Kweon YO, Kim BS, Lee CH.
    Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
    [Abstract] [Full Text] [Related]

  • 3. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
    Lee SH, Song IH, Noh R, Kang HY, Kim SB, Ko SY, Lee ES, Kim SH, Lee BS, Kim AN, Chae HB, Kim HS, Lee TH, Kang YW, Lee JD, Lee HY.
    BMC Cancer; 2015 Apr 08; 15():236. PubMed ID: 25885683
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis.
    Jeong SW, Jang JY, Shim KY, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim KH, Kim JH.
    Gut Liver; 2013 Nov 08; 7(6):696-703. PubMed ID: 24312711
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
    Lee S, Kim BK, Kim SU, Park SY, Kim JK, Lee HW, Park JY, Kim DY, Ahn SH, Tak WY, Kweon YO, Lee JI, Lee KS, Kim HJ, Han KH.
    J Gastroenterol Hepatol; 2014 Nov 08; 29(7):1463-9. PubMed ID: 25273508
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Chen L, Su H, Shao H, Xu K, Liang S, Liu J.
    Hepatogastroenterology; 2014 May 08; 61(131):802-8. PubMed ID: 26176077
    [Abstract] [Full Text] [Related]

  • 12. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
    Kim HY, Park JW, Joo J, Kim H, Woo SM, Lee WJ, Kim CM.
    J Gastroenterol Hepatol; 2013 Nov 08; 28(11):1756-61. PubMed ID: 23800278
    [Abstract] [Full Text] [Related]

  • 13. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
    Cho Y, Lee JH, Lee DH, Cho EJ, Yu SJ, Yi NJ, Lee KW, Kim YJ, Yoon JH, Suh KS.
    Oncotarget; 2017 Jul 18; 8(29):47555-47564. PubMed ID: 28548930
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
    Kawaoka T, Aikata H, Hyogo H, Morio R, Morio K, Hatooka M, Fukuhara T, Kobayashi T, Naeshiro N, Miyaki D, Hiramatsu A, Imamura M, Kawakami Y, Takahashi S, Waki K, Tsuji K, Kohno H, Kohno H, Moriya T, Chayama K.
    J Dig Dis; 2015 Sep 18; 16(9):505-12. PubMed ID: 26121102
    [Abstract] [Full Text] [Related]

  • 16. Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.
    Ye HH, Ye JZ, Xie ZB, Peng YC, Chen J, Ma L, Bai T, Chen JZ, Lu Z, Qin HG, Xiang BD, Li LQ.
    World J Gastroenterol; 2016 Apr 07; 22(13):3632-43. PubMed ID: 27053855
    [Abstract] [Full Text] [Related]

  • 17. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
    Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E, Boni L, Laffi G, Di Costanzo F, Marra F.
    World J Gastroenterol; 2014 Jan 21; 20(3):786-94. PubMed ID: 24574751
    [Abstract] [Full Text] [Related]

  • 18. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma.
    Li J, Hou Y, Cai XB, Liu B.
    World J Gastroenterol; 2016 Apr 21; 22(15):4034-40. PubMed ID: 27099447
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
    Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM.
    J Hepatol; 2012 Oct 21; 57(4):821-9. PubMed ID: 22727733
    [Abstract] [Full Text] [Related]

  • 20. Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20.
    Patt Y, Rojas-Hernandez C, Fekrazad HM, Bansal P, Lee FC.
    Oncologist; 2017 Oct 21; 22(10):1158-e116. PubMed ID: 28687627
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.